Presented Chris Chen PhD, CEO at WuXi Biologics and Dr. Sébastien Ribault, Senior Director, Global Delivery and Sales, BioReliance® End-to-End Solutions at Merck.

Biopharmaceutical plants will look different in the future. Agility and flexibility for rapidly changing product portfolios, single-use technologies, continuous manufacturing, small batch manufacturing, and personalised medicine manufacturing will not only change the face of a plant but will also require other logistics models. Chris will explain WuXi Biologics’ approach to biological facilities of the future.

свернуть